Colorectal cancer (CRC) is a highly prevalent disease characterized by high mortality rates and often complicated by metastatic dissemination, most frequently to the liver. Surgical resection constitutes the most effective therapeutic option for patients with hepatic metastases, although this option is not always feasible due to the extent of metastatic spread. The development of metastases is influenced by intricate interactions between cancer and immune cells. Tumor-associated immune cells, particularly myeloid cells, have been shown to play critical roles in the metastatic cascade. Indeed, the recruitment of inflammatory monocytes, 1 macrophages 2 and granulocytes 3 to the metastatic microenvironment is essential for the development of pulmonary metastases from breast carcinomas and other solid tumors. Although the role of myeloid cells in the metastatic dissemination of CRC to the liver has been less extensively studied, a tumor-infiltrating myeloid cell population (CD11b + /CD34 + /Gr1 − cells) has been shown to promote the hepatic expansion of CRC cells in the liver. 4 Using murine models, we have recently characterized three myeloid cell populations (CD11b/Gr1 high , CD11b/Gr1 mid and CD11b/Gr1 low ) in the hepatic tumor microenvironment, each featuring a distinct morphology, distinct surface marker expression and distinct profile of secreted inflammatory mediators. Among these myeloid cell subsets, CD11b/Gr1 mid cells increased dramatically as metastases progressed. This pattern of myeloid cell accumulation was tumor-specific, as we observed it only in mice bearing metastasis from MC38 CRC and Lewis lung carcinoma (LLC) but not B16F1 melanoma cells. 5 We have also demonstrated the functional importance of CD11b/Gr1 mid and CD11b/Gr1 low myeloid cells in the progression of hepatic metastases. The depletion of these cells (as obtained by the administration of diphtheria toxin A in transgenic mice bearing the diphtheria toxin receptor under the control of the CD11b promoter) in animals bearing established liver metastases caused a striking decrease in hepatic tumor burden. Previous studies have established that tumor-infiltrating myeloid cells can support the metastatic cascade at various levels, including early stages of the metastatic process (i.e., the formation of pre-metastatic niche, invasion and extravasation from blood vessels), 1 (Fig. 1) . The inhibition of CCL2 signaling using a CCL2-specific lentiviral-based shorthairpin RNA (shRNA) as well as the absence of its cognate receptor in Ccr2 knockout mice inhibited the recruitment of CD11b/Gr1 mid cells, resulting in a marked reduction of tumor burden. The deregulation of CCL2/CCR2 is common in cancer, and it has been implicated in the progression of a number of different primary neoplasms. 6, 7 We have analyzed the serum of CRC patients, observing a correlation between the levels of CCL2 and disease stage, in line with previous results. 6, 7 In addition, the analysis of tissue samples from CRC patients bearing hepatic metastases revealed CD11b + /CCR2 + cells tumor-infiltrating immune cells play important roles in metastasis. we have recently revealed the recruitment of a specific myeloid cell subset (CD11b/Gr1 mid ) to hepatic metastases. such a recruitment relies on CCL2/CCr2 signaling and acts to sustain metastatic growth. A similar cell subset was identified in patients bearing hepatic metastases of colorectal cancer, highlighting the potential therapeutic relevance of our findings.
the host immune system to their own ends. However, clinical benefits may only be gained by targeting multiple chemokines/chemokine receptors, presumably in a patient-specific manner. A better understanding of the roles of tumor-infiltrating myeloid cells in metastatic dissemination is urgently required to specifically target the mechanisms whereby these cells influence metastatic progression.
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that the redundancy of the chemokine network may limit the efficacy of targeting a single component of this system.
Taken together, our results highlight the importance of myeloid cells in the growth of hepatic metastases. The fact that myeloid cells have been similarly implicated in the development of metastasis from other neoplasms indicates that their recruitment to the tumor microenvironment is a fundamental process, modulating multiple steps in the metastatic cascade, and confirm that metastasizing tumor cells are capable of manipulating ( Fig. 1, inset) sharing features with the tumor-infiltrating CD11b/Gr1 mid cells identified in our murine model. Chemokine/chemokine receptor pairs represent attractive therapeutic targets, yet trials aimed at inhibiting aberrant chemokine/cytokine networks in cancer patients have provided relatively inconclusive results to date. 8 Although our studies demonstrate the importance of CCL2/CCR2 signaling in the development of hepatic metastasis, we have also shown that the inhibition of CCL2 only generate a temporary delay in metastatic growth, suggesting were found in metastatic liver tissues from some colorectal cancer patients (inset).
